Bischoff P, Reck M, Overbeck T, Christopoulos P, et al. Outcome of first-line treatment with pembrolizumab according to KRAS/TP53 mutational status for non-squamous PD-L1 high (>/=50%) NSCLC in the German National Network Genomic Medicine Lung Cancer (nNGM). J Thorac Oncol 2023 Dec 12:S1556-0864(23)02423.
PMID: 38096950